GMTX RSI Chart
Last 7 days
-2.1%
Last 30 days
-8.0%
Last 90 days
4.2%
Trailing 12 Months
3629.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 0 | 0 | 0 | 138.5M |
2022 | 0 | 0 | 0 | 0 |
2021 | 0 | 0 | 0 | 0 |
2020 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Oct 26, 2022 | leonard braden michael | sold | -47,025 | 2.09 | -22,500 | - |
May 31, 2022 | piekos brian | acquired | 10,856 | 1.09 | 9,960 | cfo |
Apr 13, 2022 | leonard braden michael | bought | 291,604 | 1.5206 | 191,769 | - |
Apr 12, 2022 | leonard braden michael | bought | 75,075 | 1.365 | 55,000 | - |
Apr 12, 2022 | leonard braden michael | bought | 290,193 | 1.4243 | 203,744 | - |
Apr 11, 2022 | leonard braden michael | bought | 681,057 | 1.35 | 504,487 | - |
May 14, 2021 | meyenburg jason patrick | bought | 122,929 | 9.4561 | 13,000 | president & ceo |
May 14, 2021 | piekos brian | bought | 72,431 | 9.462 | 7,655 | chief financial officer |
Feb 05, 2021 | tananbaum james b. | acquired | - | - | 2,928,750 | - |
Feb 05, 2021 | tananbaum james b. | acquired | 15,000,000 | 10.00 | 1,500,000 | - |
Which funds bought or sold GMTX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Nov 14, 2022 | Foresite Capital Opportunity Management V, LLC | unchanged | - | -121,000 | 3,994,000 | 11.99% |
May 16, 2022 | Amalgamated Financial Corp. | new | - | 4,000 | 4,000 | -% |
May 16, 2022 | Parametric Portfolio Associates LLC | sold off | -100 | -126,000 | - | -% |
Unveiling Gemini Therapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Gemini Therapeutics, Inc. News
Income Statement (Quarterly) | |||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 | 2020Q3 |
Revenue | -100.0% | - | 138,508,000 | 34,148,000 | - | - | - | - | - | - | - | - | 120,750,000 |
Operating Expenses | 71.5% | 29,714,000 | 17,328,000 | 25,125,000 | 15,021,000 | 10,479,000 | 12,015,000 | 9,960,000 | -20,327,000 | 18,450,000 | 16,320,000 | 9,794,000 | 7,949,000 |
S&GA Expenses | 36.7% | 7,149,000 | 5,228,000 | 4,945,000 | 5,005,000 | 2,593,000 | 4,301,000 | 2,139,000 | -9,414,000 | 4,995,000 | 5,478,000 | 2,096,000 | 1,222,000 |
R&D Expenses | 86.5% | 22,565,000 | 12,100,000 | 20,180,000 | 10,016,000 | 7,886,000 | 7,714,000 | 7,821,000 | -10,913,000 | 13,455,000 | 10,842,000 | 7,698,000 | 6,727,000 |
EBITDA Margin | -Infinity% | -0.55 | - | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | - | - | - | - | - | 41,000 | 48,000 | 66,000 | 85,000 | 104,000 | 121,000 | 4,519,000 | 2,047,000 |
Income Taxes | 33.3% | 32,000 | 24,000 | 23,000 | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | -47.9% | -23,547,000 | -15,923,000 | -22,758,000 | -11,244,000 | -16,150,000 | -9,580,000 | -9,853,000 | - | - | - | -311,584 | -500,911 |
EBT Margin | -Infinity% | -0.55 | - | - | - | - | - | - | - | - | - | - | - |
Net Income | -47.9% | -23,579,000 | -15,947,000 | -22,781,000 | -11,244,000 | -16,150,000 | -9,580,000 | -9,853,000 | 18,077,000 | -18,551,000 | -16,447,000 | -14,315,000 | -10,003,000 |
Net Income Margin | -Infinity% | -0.55 | - | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | -39.8% | -17,799,000 | -12,736,000 | -35,495,000 | -9,677,000 | -9,711,000 | -9,214,000 | -13,801,000 | 19,491,000 | - | - | - | - |
Balance Sheet | ||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Assets | -2.3% | 368 | 376 | 384 | 244 | 200 | 106 | 113 | 124 | 92.00 | 156 | 172 | 189 | 156 | 122 | - |
Current Assets | -2.3% | 366 | 374 | 382 | 242 | 198 | 105 | 113 | 124 | 90.00 | 155 | 171 | 189 | 5.00 | 2.00 | - |
Cash Equivalents | -2.7% | 361 | 371 | 378 | 236 | 195 | 56.00 | 65.00 | 74.00 | 88.00 | 150 | 168 | 185 | 26.00 | 14.00 | 6.00 |
Net PPE | -7.1% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - |
Liabilities | 30.5% | 23.00 | 18.00 | 13.00 | 11.00 | 24.00 | 1.00 | 6.00 | 13.00 | 15.00 | 15.00 | 15.00 | 18.00 | 30.00 | 5.00 | - |
Current Liabilities | 48.7% | 21.00 | 14.00 | 10.00 | 10.00 | 23.00 | 1.00 | 6.00 | 13.00 | 13.00 | 13.00 | 12.00 | 14.00 | 25.00 | 1.00 | 0.00 |
Shareholder's Equity | -3.9% | 345 | 359 | 371 | 233 | 177 | 105 | 107 | 112 | 125 | 141 | 158 | 171 | 5.00 | 5.00 | 0.00 |
Retained Earnings | -14.3% | -188 | -165 | -150 | -135 | -112 | -210 | -207 | -199 | -65.39 | -166 | -148 | -131 | -112 | -0.50 | 0.00 |
Additional Paid-In Capital | 1.9% | 534 | 524 | 522 | 368 | 289 | 315 | 314 | 312 | 1.00 | 308 | 306 | 303 | 91.00 | 6.00 | 0.00 |
Shares Outstanding | 0.9% | 24.00 | 24.00 | 23.00 | 20.00 | 17.00 | 1.00 | 1.00 | 1.00 | 1.00 | 4.00 | 4.00 | 3.00 | - | - | - |
Cashflow (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Cashflow From Operations | -138.0% | -17,796 | -7,476 | -12,724 | -35,466 | -9,665 | -9,692 | -9,194 | -13,701 | 19,498 | -16,097 | -15,928 | -15,007 | -4,539 | -190 | -7,033 | -9,881 |
Share Based Compensation | 51.7% | 1,927 | 1,270 | 1,309 | 1,024 | 993 | 382 | 382 | 332 | -5,607 | 1,659 | 2,862 | 1,593 | 590 | 161 | 138 | 94.00 |
Cashflow From Investing | 93.3% | -3.00 | -45.00 | -12.00 | -29.00 | -12.00 | -19.00 | -20.00 | -100 | -7.00 | 120,689 | - | - | - | -120,750 | - | - |
Cashflow From Financing | 1586.5% | 7,758 | 460 | 153,855 | 77,306 | 148,815 | 22.00 | 86.00 | 55.00 | -102,730 | -1,250 | -1,581 | 195,490 | 70.00 | 122,378 | 9.00 | 20,094 |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating expenses: | ||
Research and development | $ 69,264 | $ 33,437 |
General and administrative | 21,861 | 14,038 |
Total operating expenses | 91,125 | 47,475 |
Loss from operations | (91,125) | (47,475) |
Other income (expense), net: | ||
Interest income | 14,797 | 709 |
Change in fair value of derivative liability | 0 | (61) |
Other expense | (2) | 0 |
Total other income (expense), net | 14,795 | 648 |
Loss before income taxes | (76,330) | (46,827) |
Income tax expense | (99) | 0 |
Net loss and comprehensive loss | (76,429) | (46,827) |
Net loss attributable to common stockholders-basic | (76,429) | (46,827) |
Net loss attributable to common stockholders-diluted | $ (76,429) | $ (46,827) |
Weighted-average common shares outstanding-basic | 22,315,877 | 1,039,490 |
Weighted-average common shares outstanding-diluted | 22,315,877 | 1,039,490 |
Net loss per share attributable to common stockholders-basic | $ (3.42) | $ (45.05) |
Net loss per share attributable to common stockholders-diluted | $ (3.42) | $ (45.05) |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 360,382 | $ 194,611 |
Prepaid expenses and other current assets | 5,280 | 3,880 |
Total current assets | 365,662 | 198,491 |
Property and equipment, net | 170 | 168 |
Right-of-use assets, operating leases | 1,930 | 1,430 |
Other assets | 234 | 116 |
Total assets | 367,996 | 200,205 |
Current liabilities: | ||
Accounts payable | 12,629 | 16,162 |
Accrued expenses | 8,145 | 6,109 |
Operating lease liabilities, current | 665 | 307 |
Total current liabilities | 21,439 | 22,578 |
Operating lease liabilities, non-current | 1,436 | 1,027 |
Total liabilities | 22,875 | 23,605 |
Commitments and contingencies (Note 14) | ||
Stockholders' equity: | ||
Common stock, $0.0001 par value; 100,000,000 shares authorized as of December 31, 2023 and 2022; 24,360,233 and 17,405,231 shares issued as of December 31, 2023 and 2022, respectively; and 24,360,233 and 17,403,315 shares outstanding as of December 31, 2023 and 2022, respectively | 2 | 2 |
Additional paid-in capital | 533,764 | 288,814 |
Accumulated deficit | (188,645) | (112,216) |
Total stockholders' equity | 345,121 | 176,600 |
Total liabilities and stockholders' equity | $ 367,996 | $ 200,205 |